Pfizer, Merck KGaA launch two more PhIII trials for avelumab

John Carroll

The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS